MedDataX Logo

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

NCT ID: NCT04422899

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-28

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AIV007 is a multiple kinase inhibitor of vascular endothelial growth factor receptors (VEGFR 1, -2 \& -3); fibroblast growth factor receptors (FGFR-1, -2, -3 \& -4); and platelet-derived growth factor receptors (PDGFR-α \& β)1. Lenvatinib is the active pharmaceutical ingredient in AIV007 formulation that is FDA-approved for oral administration for patients with advanced renal cell carcinoma (RCC), differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), and advanced endometrial carcinoma (Lenvima USPI 2021; NDA 206947). AIV007 is a novel, thermoresponsive gel suspension for intravitreal administration proposed to form a durable depot inside the eye. This monotherapy is being evaluated for the treatment of retinal and choroidal vascular disease. A single intravitreal treatment in 3 subjects was evaluated using 2 doses to evaluate depot formation, safety and biological activity by measuring visual acuity, reduction in retinal fluids associated with vision and effects of fibrosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-related Macular Degeneration

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Neovascular Age-Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AIV007 Treatment Dose 1

Intravitreal, Dose 1

Group Type EXPERIMENTAL

AIV007

Intervention Type DRUG

intravitreal

AIV007 Treatment Dose 2

Intravitreal, Dose 2

Group Type EXPERIMENTAL

AIV007

Intervention Type DRUG

intravitreal

AIV007 Treatment Dose 3

Intravitreal, Dose 3

Group Type EXPERIMENTAL

AIV007

Intervention Type DRUG

intravitreal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AIV007

intravitreal

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects aged ≥ 50 years
2. Subjects must provide written informed consent before any study-related procedures are performed
3. Active subfoveal CNV in the study eye secondary to AMD that has previously been treated with at least 3 intravitreal injections of an anti-VEGF agent
4. BCVA in the study eye

1. Sentinel subjects only: 65 ETDRS letters (20/50 Snellen equivalent) or worse
2. All other subjects: 78 to 35 ETDRS letters (20/32 to 20/200 Snellen equivalent)
5. Clear ocular media and adequate pupil dilation in both eyes to permit good quality photographic imaging

Exclusion Criteria

1. Previous treatment for nAMD in the study eye, other than standard-of-care anti- VEGF IVT injection, eg, cell therapy, brachytherapy, gene therapy
2. Treatment with anti-VEGF in the non-study eye 2 weeks prior to baseline
3. Presence of diabetic retinopathy or glaucoma in either eye
4. Spherical equivalent for refractive error in the study eye of worse than 8.0 diopters of myopia (prior to cataract or refractive surgery)
5. Presence of active infection or inflammation within 30 days prior to screening
6. Presence of contraindications to anti-VEGF treatment, including myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, transient ischemic attack, or stroke within the last 3 months of baseline
7. Uncontrolled hypertension or diabetes mellitus
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AiViva BioPharma, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Salehi Retina Institute

Huntington Beach, California, United States

Site Status

Retina Research Institute of Texas

Abilene, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AIV007-E01

Identifier Type: -

Identifier Source: org_study_id